“In terms of efficacy, some studies have shown that renal denervation can achieve a clinically relevant reduction of office and ambulatory blood pressure in patients with difficult-to-control hypertension. There is a need for more research to identify the pathophysiology of the condition and to select the best patients who will benefit from treatment with the procedure,” Tsioufis stated.
“Maybe we are moving away from Symplicity to complexity, in terms of how we deliver energy and where the sweet spots for renal denervation are,” F. Mahfoud commented. “On top of it there may be a learning curve for renal denervation; there is a lot more to learn and a lot more to understand,” concluded F. Mahfoud.
“Renal denervation was developed as a promising therapy for the treatment of patients who suffer from resistant hypertension lacking treatment alternatives,” stated William Wijns, EuroPCR Course Co-director.
Our mission: To reduce the burden of cardiovascular disease
© 2018 European Society of Cardiology. All rights reserved